Overview of all our clinical studies and available biobanks
NORMAL CONTROL PEDIATRIC POPULATIONS
Leipzig school children project:
= representative normal populations
n~3000 total; n~1200 for consented DNA analysis
LIFE Child Health:
= longitudinal childhood population including detailed anthropometric and metabolic phenotyping
n>3500 total (ongoing)
More information
OBESE PEDIATRIC POPULATIONS
Leipzig Obesity Childhood Cohort:
incl. detailed phenotyping and oGTT's n>2200 (incl. follow-ups n>500)
Leipzig Atherobesity Childhood Cohort:
obese children n=100 and lean children n=70
incl. detailed metabolic and cardiovascular phenotyping and MRI scans as well as follow-up data
LIFE Child Obesity:
= longitudinal childhood population incl. detailed metabolic phenotyping
n>340 participants in total (n>680 visits, incl. follow-ups)
More information
SPECIAL POPULATIONS
Intervention in obese children:
= inpatients, 6 week exercise intervention
n=62 incl. detailed phenotyping
Leipzig Circadian Rhythm Cohort:
= young healthy lean and obese adults incl. frequent serum sampling over 30 h
n=59 incl. detailed metabolic phenotyping
Adipose tissue pediatric biobank:
= adipose tissue samples from lean and obese children incl. consented DNA analysis
n=467 total currently (incl. 395 samples), ongoing study
PEDIATRIC POPULATIONS FOR GENOTYPING
n~1000 incl. MetaboChip data:
cohorts contributed to MAGIC and EGG consortia, collaborations and publications
- Metabolic traits (Scott, Nature genet Epub) collaboration
- intrauterine growth (Hokoshi, Nature Epub) collaboration
- available for own analyses
n>2000 incl. targeted (candidate) genetic analyses and GWAS replication:
- FTO (Dina, Nat genet 2007) collaboration
- GWAS (Meyre, Nat genet 2009; Scherag, PLoS genet 2010) collaboration
- TCF7L2 (Körner, JCEM 2007)
- Metabolic traits (Windholz, PLoS One 2011)
- GPR120 (Ichimura, Nature Epub) collaboration
n~3000 incl. ExomeChip data (currently done in collaboration with
Wellcome Trust, UK):
- available for own analyses (in collaboration with WTTC)
SUMMARY
n~5000 data sets from according cohorts (ongoing)
n~2750 lean, n~1750 obese (ongoing)
n~2800 incl. consented DNA analysis (ongoing)
n>1800 incl. oGTT's (ongoing)
SETMELANOTIDE PHASE 2 TREATMENT TRIAL IN PATIENTS WITH RARE GENETIC DISORDERS OF OBESITY
Besides the common multifactorial and polygenetic causes of obesity, there are also rare cases of single gene mutations interfering with the hypothalamic control of satiety and thus leading to obesity. Those patients are mostly severely affected and present with extreme early-onset obesity and hyperphagia. Setmelanotide, a new drug targeting the MC4-receptor dependent hypothalamic satiety control has shown promising results during the first years of clinical experience. The department of pediatrics at the university hospital in Leipzig is now able to provide treatment with Setmelanotide through an international multicenter clinical trial (NCT03013543) for some of those rare genetic disorders. For more details, please contact us.
Contact details
|
Dr. med. Robert Stein |
|
Deputy PI |
|
Phone.: +49 341 9720296 |
E-Mail: robert.stein@medizin.uni-leipzig.de
Childhood Obesity Follow-up Study
Aim of the study
Obesity is a life-long burden that often starts already during childhood, although obesity-associated comorbidities such as diabetes, fatty liver disease and atherosclerosis may manifest later in life. This study aims to explore the transition of children with obesity into adulthood from a comprehensive biological, (epi) genetic, environmental and sociopsychological perspective. We will emphasize on risk factors as well as protective factors during childhood that enable the prediction of disease progression during adulthood. We are collaborating with the Helmholtz Institute for Metabolic, Obesity and Vascular Research (HIMAG), as well as the LIFE Child Study.
Who may participate?
People who meet the following requirements:
- Adults at the age of 18 and above that have been treated for obesity during childhood at the university hospital Leipzig
What happens during the study?
You will undergo the following examinations:
- Structured reporting of medical history and completion of questionnaires targeting lifestyle, environment and well-being
- determination of body measurements (weight, height, BMI etc.)
- measurement of body fat and muscle mass (bioimpedance analysis)
- blood examinations
- oral glucose tolerance testing
- sonography of common carotid artery
- sonography-based liver elastography
- 24 hour ambulatory blood pressure measurement
How long does the participation at the study take and will there be a remuneration?
The examinations take place over the course of one day (6h in total) and you will receive 50,-€ expense allowance.
You are interested?
Please do not hesitate to contact us! The study is conducted under the lead of Prof. Antje Körner and clinician scientist Dr. Robert Stein from the Department of Pediatrics.
Tel: +49 341 97 26922
Email: robert.stein@medizin.uni-leipzig.de
